Regarding the effects of the type of TNF-α inhibitor employed in our study (i.e., etanercept or adalimumab) on the levels of bone turnover markers (PINP, CTX-I) and osteoclast regulators (sRANKL, OPG) in female RA patients, our results have not demonstrated any superiority of ETA therapy in terms of preventing bone damage when compared to ADA. The gene discussed is ADA; the disease is rheumatoid arthritis.